Ipilimumab-induced neutropenia in melanoma

18Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.

Cite

CITATION STYLE

APA

Ban-Hoefen, M., Burack, R., Sievert, L., & Sahasrabudhe, D. (2016). Ipilimumab-induced neutropenia in melanoma. Journal of Investigative Medicine High Impact Case Reports, 4(3). https://doi.org/10.1177/2324709616661835

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free